| 1 |
32777735 | Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities. | 2020 Aug |
1 |
| 2 |
32955829 | Enasidenib and ivosidenib in AML. | 2020 Oct |
1 |
| 3 |
31105869 | Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production. | 2019 Apr 12 |
1 |
| 4 |
31257503 | IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells. | 2019 Aug |
1 |
| 5 |
29769206 | Targeting the IDH2 Pathway in Acute Myeloid Leukemia. | 2018 Oct 15 |
1 |
| 6 |
29773061 | Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer. | 2018 |
1 |
| 7 |
30013764 | The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. | 2018 Jul |
1 |
| 8 |
30506321 | Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. | 2018 Nov 30 |
1 |
| 9 |
27721426 | Isocitrate dehydrogenase mutations in myeloid malignancies. | 2017 Feb |
1 |
| 10 |
28536275 | SIRT3-Mediated Dimerization of IDH2 Directs Cancer Cell Metabolism and Tumor Growth. | 2017 Aug 1 |
1 |
| 11 |
29290954 | WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression. | 2017 Dec 5 |
1 |
| 12 |
26188014 | Isocitrate dehydrogenase mutations in gliomas. | 2016 Jan |
1 |
| 13 |
26819452 | Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. | 2016 Apr 15 |
2 |
| 14 |
26960449 | Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis. | 2016 |
2 |
| 15 |
27005468 | IDH mutations in cancer and progress toward development of targeted therapeutics. | 2016 Apr |
2 |
| 16 |
27049945 | Reductive carboxylation supports redox homeostasis during anchorage-independent growth. | 2016 Apr 14 |
1 |
| 17 |
27621679 | IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. | 2016 |
1 |
| 18 |
25324168 | Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. | 2015 Jan |
1 |
| 19 |
25753205 | A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma. | 2015 Apr 17 |
2 |
| 20 |
24880135 | The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. | 2014 Dec |
1 |
| 21 |
23630074 | What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. | 2013 Apr 15 |
1 |
| 22 |
22343896 | Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. | 2012 Feb 15 |
1 |
| 23 |
22397365 | Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. | 2012 Mar 7 |
1 |
| 24 |
23226729 | Altered expression levels of IDH2 are involved in the development of colon cancer. | 2012 Nov |
1 |
| 25 |
21647154 | IDH1 and IDH2 mutations in pediatric acute leukemia. | 2011 Oct |
2 |
| 26 |
21889589 | A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies. | 2011 Nov |
1 |
| 27 |
22106302 | Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. | 2011 Dec 6 |
1 |
| 28 |
20603105 | IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. | 2010 Jul 30 |
1 |
| 29 |
20972461 | Cancer-associated IDH mutations: biomarker and therapeutic opportunities. | 2010 Dec 9 |
1 |
| 30 |
19996293 | Mutant metabolic enzymes are at the origin of gliomas. | 2009 Dec 15 |
1 |